{"id":13109,"date":"2010-05-15T10:30:00","date_gmt":"2010-05-15T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/la-scadenza-dei-brevetti-costera-100-mld-di-dollari-a-big-pharma\/"},"modified":"2010-05-15T10:30:00","modified_gmt":"2010-05-15T08:30:00","slug":"la-scadenza-dei-brevetti-costera-100-mld-di-dollari-a-big-pharma","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/la-scadenza-dei-brevetti-costera-100-mld-di-dollari-a-big-pharma\/","title":{"rendered":"Patent expiration will cost Big Pharma $100 billion"},"content":{"rendered":"<p><img decoding=\"async\" style=\"width: 100px\" id=\"DLImmagini__ctl160_Img\" border=\"0\" alt=\"\" src=\"http:\/\/www.informatori.aiisf.it\/img\/Archivio\/\/N3298.jpg\" width=\"100\" \/>&nbsp; The loss of patent coverage of products on the market will cost Big Pharma about 100 billion dollars over the next 5 years, while the value that soon-to-be-introduced medicines will bring to the market will be limited to 30 billion. These are the estimates of Nils Behnke, partner of the consulting firm Bain &amp; Company. Four main strategies currently followed by pharmaceutical companies to meet these forecasts: expand the R&amp;D pipeline also thanks to outsourcing; expand into emerging markets; increase sales of non-patented products as well; experiment with new pricing strategies in different countries.<\/p>\n<p>The Financial Times Pg.10 \u2013 13\/05\/2010 <img decoding=\"async\" style=\"width: 100px\" id=\"DLImmagini__ctl156_Img\" border=\"0\" alt=\"\" src=\"http:\/\/www.informatori.aiisf.it\/img\/Archivio\/\/N3294.jpg\" width=\"100\" \/><\/p>","protected":false},"excerpt":{"rendered":"<p>&nbsp; La perdita della copertura brevettuale dei prodotti in commercio coster&agrave; circa 100 mld di dollari a Big pharma nei prossimi 5 anni, mentre il valore che i medicinali di prossima introduzione porteranno sul mercato sar&agrave; limitato a 30 mld. Queste le stime di Nils Behnke, partner della societ&agrave; di consulenza Bain &amp; Company. Quattro &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13109","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13109"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13109\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}